Cited by 2,003Bone health and osteoporosis researchBone health and treatmentsHip and Femur Fractures

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Open access

Lyles, Kenneth W., Colón-Emeric, Cathleen S., Magaziner, Jay S., Adachi, Jonathan D., Pieper, Carl F., Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A., Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K., Abrams, Ken, Orloff, John J., Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven·2007·New England Journal of Medicine

DOI 10.1056/nejmoa074941PMC PMC2324066

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa074941

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Vitamin D Deficiency
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,396
Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281

Show all 35 references

Research works printed but not linked: 2

Davidson CW, 2001, N Z Med J, 114, 329
2003, World Health Organ Tech Rep Ser, 921, 1

Sorted by citations

Items 301–400 of 1,000

Intravenous Bisphosphonate Therapy and Bisphosphonate-Related Osteonecrosis of the Jaws
Dodson, T. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.12.004 · Cited by 66
Screening and Treatment of Osteoporosis After Hip Fracture: Comparison of Sex and Race
Antonelli, M. J., Einstadter, D., & Magrey, M. (2014) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2014.01.009 · Cited by 65
Prevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies
Bonura, F. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2021 · Cited by 66
Current approaches to osteoporosis treatment
Lim, S. Y., & Bolster, M. B. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000169 · Cited by 65
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 64
The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults
Bhadada, S. K., Chadha, M. D., Sriram, U., Pal, R., Paul, T. V., Khadgawat, R., Joshi, A. S., Bansal, B., Kapoor, N., Aggarwal, A., et al. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00954-1 · Cited by 65
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases
Polascik, T. J. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s3169 · Cited by 64
Short- and long-term mortality in males and females with fragility hip fracture in Norway. A population-based study
Diamantopoulos, A. P., Hoff, M., Hochberg, Skoie, & Haugeberg, G. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s45468 · Cited by 64
Treatment of osteopenia
Eriksen, E. F. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9187-z · Cited by 66
Self-citation
Inflammatory Markers and Frailty in Long‐Term Care Residents
Langmann, G. A., Perera, S., Ferchak, M. A., Nace, D. A., Resnick, N. M., & Greenspan, S. L. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14876 · Cited by 64
2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)
Ferrari, S., Lippuner, K., Lamy, O., & Meier, C. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20352 · Cited by 64
The Role of the Orthopaedic Surgeon in Minimizing Mortality and Morbidity Associated With Fragility Fractures
Ekman, E. F. (2010) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-201005000-00004 · Cited by 63
Bisphosphonate-Induced Osteonecrosis of the Jaws, Bone Markers, and a Hypothesized Candidate Gene
Lehrer, S., Montazem, A. H., Ramanathan, L. V., Pessin, M. S., Pfail, J. L., Stock, R. G., & Kogan, R. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.09.015 · Cited by 63
Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.05.013 · Cited by 66
A reappraisal of generic bisphosphonates in osteoporosis
Kanis, J. А., Reginster, J., Kaufman, J., Ringe, J. D., Adachi, J. D., Hiligsmann, M., Rizzoli, R., & Cooper, C. C. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1796-6 · Cited by 63
Self-citation
Osteoporosis treatments and adverse events
Solomon, D. H., Rekedal, L., & Cadarette, S. M. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832ca433 · Cited by 63
The treatment gap: The missed opportunities for osteoporosis therapy
Fuggle, N. R., Curtis, E. M., Clynes, M. A., Zhang, J., Ward, K. A., Javaid, M. K., Harvey, N. C., Dennison, E. M., & Cooper, C. C. (2020) · Bone · doi:10.1016/j.bone.2020.115833 · Cited by 62
Self-citation
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
Lambrinoudaki, I. V. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2046 · Cited by 62
Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age
Seeman, E., Boonen, S., Borgström, F., Vellas, B. J., Aquino, J., Semler, J., Benhamou, C.-L., Kaufman, J., & Reginster, J. (2009) · Bone · doi:10.1016/j.bone.2009.12.006 · Cited by 63
Self-citation
Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy
Bhoopalam, N., Campbell, S. C., MORITZ, T. E., Broderick, W. R., Iyer, P., Arcenas, A. G., Veldhuizen, P. J. V., FRIEDMAN, N. C., Reda, D. J., Warren, S. R., et al. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.07.046 · Cited by 62
Current Concepts Review: Risk Factors for Nonunions in Foot and Ankle Arthrodeses
Thevendran, G., Younger, A. S. E., & Pinney, S. J. (2012) · Foot & Ankle International · doi:10.3113/fai.2012.1031 · Cited by 62
Low-trauma fractures without osteoporosis
Lespessailles, É., Cortet, B., Legrand, E., Guggenbuhl, P., & Roux, C. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3921-7 · Cited by 64
Bisphosphonates in the Treatment of Osteoporosis
Diab, D. L., & Watts, N. B. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.007 · Cited by 61
Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men
Bolland, M. J., Grey, A. B., Horne, A. M., Briggs, S. E., Thomas, M. G., Ellis-Pegler, R. B., Gamble, G. D., & Reid, I. R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1424 · Cited by 61
Osteoporosis
Gehrig, L. M. B., Lane, J., & O’Connor, M. I. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200806000-00028 · Cited by 61
Bisphosphonates for post-menopausal osteoporosis: are they all the same?
Rizzoli, R. (2011) · QJM · doi:10.1093/qjmed/hcq259 · Cited by 61
The Clinical Impact of Fracture Liaison Services: A Systematic Review
Barton, D. W., Piple, A. S., Smith, C. T., Moskal, S. A., & Carmouche, J. J. (2021) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151459320979978 · Cited by 60
Secondary prevention of osteoporotic fractures—an “OPTIMAL” model of care from Singapore
Chandran, M., Tan, M. Z.-W., Cheen, M. H. H., Tan, S., Leong, M. Q., & Lau, T. C. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2368-8 · Cited by 60
Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function
Misra, J., Mohanty, S. T., Madan, S. S., Fernandes, J. A., Ebetino, F. H., Russell, R. G. G., & Bellantuono, I. (2015) · Stem Cells · doi:10.1002/stem.2255 · Cited by 60
Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates
Sharma, A., Einstein, A. J., Vallakati, A., Arbab‐Zadeh, A., Walker, M. D., Mukherjee, D., Homel, P., BORER, J. S., & Lichstein, E. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.03.008 · Cited by 59
Locally Delivered Bisphosphonate for Enhancement of Bone Formation and Implant Fixation
Bobyn, J., McKenzie, K., Karabasz, D., Krygier, J. J., & Tänzer, M. (2009) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00518 · Cited by 59
Common mechanisms and holistic care in atherosclerosis and osteoporosis
Szekanecz, Z., Raterman, H. G., Pethő, Z., & Lems, W. F. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1805-7 · Cited by 59
Effects of bisphosphonates on osteoporosis: Focus on zoledronate
Oryan, A., & Sahvieh, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118681 · Cited by 58
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density
van der Burgh, A. C., de Keyser, C. E., Zillikens, M. C., & Stricker, B. H. C. (2021) · Drugs · doi:10.1007/s40265-021-01625-8 · Cited by 60
Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions
Dimai, H. P., & Fahrleitner‐Pammer, A. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101780 · Cited by 58
Deprescribing in the Last Year of Life
Hardy, J. E., & Hilmer, S. N. (2011) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2011.tb00684.x · Cited by 58
Closing the gap in postfracture care at the population level: a randomized controlled trial
Leslie, W. D., LaBine, L., Klassen, P., Dreilich, D., & Caetano, P. A. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.111158 · Cited by 58
Is Withholding Osteoporosis Medication After Fracture Sometimes Rational? A Comparison of the Risk for Second Fracture Versus Death
Curtis, J. R., Arora, T., Matthews, R. S., Taylor, A. J., Becker, D. J., Colon-Emeric, C. S., Kilgore, M. L., Morrisey, M. A., Saag, K. G., Safford, M. M., et al. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2009.12.004 · Cited by 58
Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital’s fracture liaison service between January 2010 and December 2011
Dehamchia-Rehailia, N., Ursu, D., Henry-Desailly, I., Fardellone, P., & Paccou, J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2774-6 · Cited by 58
Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment
Hershman, D. L., McMahon, D. J., Crew, K. D., Shao, T. H., Cremers, S., Brafman, L., Awad, D., & Shane, E. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1366 · Cited by 57
Increased Risk of Stroke in the Year After a Hip Fracture
Kang, J., Chung, S., Xirasagar, S., Jaw, F.-S., & Lin, H. (2010) · Stroke · doi:10.1161/strokeaha.110.595538 · Cited by 57
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
Carbonare, L. D., Zanatta, M., Gasparetto, A., & Valenti, M. T. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6285 · Cited by 57
Macrophage Depletion by Free Bisphosphonates and Zoledronate-Loaded Red Blood Cells
Sabatino, R., Antonelli, A., Battistelli, S., Schwendener, R. A., Magnani, M., & Rossi, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101260 · Cited by 56
Osteoporosis in men
Walsh, J., & Eastell, R. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.171 · Cited by 57
Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
Miyauchi, A., Dinavahi, R. V., Crittenden, D. B., Yang, W., Maddox, J., Hamaya, E., Nakamura, Y., Libanati, C. R., Grauer, A., & Shimauchi, J. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0608-z · Cited by 56
Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw
Hayashida, S., Yanamoto, S., Fujita, S., Hasegawa, T., Komori, T., Kojima, Y., Miyamoto, H., Shibuya, Y., Ueda, N., Kirita, T., et al. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01035-7 · Cited by 56
Nano-Based Biomaterials as Drug Delivery Systems Against Osteoporosis: A Systematic Review of Preclinical and Clinical Evidence
Salamanna, F., Gambardella, A., Contartese, D., Visani, A., & Fini, M. (2021) · Nanomaterials · doi:10.3390/nano11020530 · Cited by 57
Zoledronic acid use in cancer patients
Coleman, R. E., Cook, R. J., Hirsh, V., Major, P. P., & Lipton, A. (2010) · Cancer · doi:10.1002/cncr.25529 · Cited by 55
The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women
Komm, B. S., Morgenstern, D., Yamamoto, L. A., & Jenkins, S. N. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1099432 · Cited by 56
Parkinson's disease: A risk factor for osteoporosis
Malochet‐Guinamand, S., Durif, F., & Thomas, T. (2015) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.03.009 · Cited by 55
Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment
Shiraki, M., Kuroda, T., Shiraki, Y., Tanaka, S., Higuchi, T., & Saito, M. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0191-2 · Cited by 55
Current, new and future treatments of osteoporosis
Salari, P., Abdollahi, M. R., & Larijani, B. A. (2010) · Rheumatology International · doi:10.1007/s00296-010-1586-z · Cited by 55
Musculoskeletal health and frailty
McGuigan, F. E., Bartosch, P., & Åkesson, K. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2017.11.002 · Cited by 56
A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement
for the EUGMS Falls and Fracture Interest Group, Blain, H., the Fragility Fracture Network (FFN), Masud, T., Dargent‐Molina, P., Martin, F. C., Rosendahl, E., van der Velde, N., Bousquet, J. J., Benetos, A., et al. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0588-4 · Cited by 55
Impact of osteoporotic fracture type and subsequent fracture on mortality: the Tromsø Study
Alarkawi, D., Bliuc, D., Tran, T. S., Ahmed, L. A., Emaus, N., Bjørnerem, Å., Jørgensen, L., Christoffersen, T., & Eisman, J. A. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05174-5 · Cited by 54
Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons
Kim, J., Kwak, M. K., Han, J. J., Lee, S., Kim, H. Y., Kim, S. H., Jung, J., Lee, J. K., Lee, Y., Kwon, Y., et al. (2021) · Journal of Bone Metabolism · doi:10.11005/jbm.2021.28.4.279 · Cited by 54
Bone metabolism in diabetes: a clinician’s guide to understanding the bone–glucose interplay
Sheu, A., & White, C. (2024) · Diabetologia · doi:10.1007/s00125-024-06172-x · Cited by 55
Inappropriate Prescribing as a Predictor for Long-Term Mortality after Hip Fracture
Gosch, M., Wörtz, M., Nicholas, J. A., Doshi, H. K., Kammerlander, C., & Lechleitner, M. (2013) · Gerontology · doi:10.1159/000355327 · Cited by 54
Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid
Silverman, S. L., Kriegman, A. G., Gonçalves, J., Kianifard, F., Carlson, T. H., & Leary, E. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1448-2 · Cited by 54
Post–hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: A nationwide study in Finland
Nurmi-Lüthje, I., Sund, R., Juntunen, M., & Lüthje, P. M. J. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.375 · Cited by 54
Bisphosphonates and implants
Aspenberg, P. (2009) · Acta Orthopaedica · doi:10.1080/17453670902807466 · Cited by 54
The effects of adjuvant endocrine therapy on bone health in women with breast cancer
Ramchand, S. K., Cheung, Y.-M. M., Yeo, B. J., & Grossmann, M. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0077 · Cited by 54
Postoperative management of hip fractures: interventions associated with improved outcomes
Colon-Emeric, C. S. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.241 · Cited by 53
Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance
Hampson, G., Stone, M. D., Lindsay, J. R., Crowley, R. K., & Ralston, S. H. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00858-9 · Cited by 53
Organisational factors associated with hospital costs and patient mortality in the 365 days following hip fracture in England and Wales (REDUCE): a record-linkage cohort study
Baji, P., Patel, R., Judge, A., Johansen, A., Griffin, J., Chesser, T. J. S., Griffin, X. L., Javaid, M. K., Barbosa, E. C., Ben‐Shlomo, Y., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00086-7 · Cited by 53
Predictors of Fracture While on Treatment With Oral Bisphosphonates: A Population-Based Cohort Study
Prieto‐Alhambra, D., Pagès-Castellà, A., Wallace, G., Javaid, M. K., Judge, A., Nogués, X., Arden, N., Cooper, C. C., & Díez‐Pérez, A. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2011 · Cited by 53
Treatment of primary osteoporosis in men
Bianchi, G., & Giusti, A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s44057 · Cited by 54
Efficacy and safety of currently marketed anti-osteoporosis medications
Reginster, J., Neuprez, A., Dardenne, N., Beaudart, C., Emonts, P., & Bruyère, O. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.003 · Cited by 53
Risk of Serious Atrial Fibrillation and Stroke With Use of Bisphosphonates
Sharma, A., Chatterjee, S., Arbab‐Zadeh, A., Goyal, S., Lichstein, E., Ghosh, J., & Aikat, S. (2013) · CHEST Journal · doi:10.1378/chest.13-0675 · Cited by 54
Management of osteoporosis in patients hospitalized for hip fractures
Ip, T., Leung, J., & Kung, A. W. C. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1398-8 · Cited by 55
Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial
Patel, D. V., Bolland, M. J., Nisa, Z. U., Al‐Abuwsi, F., Singh, M., Horne, A. M., Reid, I. R., & McGhee, C. N. J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2872-5 · Cited by 52
The effect of osteoporotic treatment on the functional outcome, re-fracture rate, quality of life and mortality in patients with hip fractures: A prospective functional and clinical outcome study on 520 patients
Makridis, K. G., Karachalios, T. S., Kontogeorgakos, V. A., Badras, L. S., & Malizos, Κ. Ν. (2014) · Injury · doi:10.1016/j.injury.2014.11.031 · Cited by 52
Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis
Camm, A. J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.014 · Cited by 52
Mortality and cardiorespiratory complications in trochanteric femoral fractures: a ten year retrospective analysis
Carow, J., Carow, J. B., Coburn, M., Kim, B., Bücking, B., Bliemel, C., Bollheimer, L. C., Werner, C. J., Bach, J., & Knobe, M. (2017) · International Orthopaedics · doi:10.1007/s00264-017-3639-3 · Cited by 52
Fracture liaison service and mortality in elderly hip fracture patients: a prospective cohort study
González-Quevedo, D., Bautista-Enrique, D., Pérez-del-Río, V., Bardaji, M. F. B., Puerta, D. G. D. Q., & Tamimi, I. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05153-w · Cited by 52
Osteoporosis
Nanes, M. S., & Kallen, C. B. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.06.006 · Cited by 54
Medical problems in hip fracture patients
Chong, C., Savige, J., & Lim, W. K. (2010) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-009-1038-y · Cited by 52
Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells
Tai, T.-W., Chen, C.-Y., Su, F.-C., Tu, Y.-K., Tsai, T.-T., Lin, C.-F., & Jou, I.-M. (2017) · Scientific Reports · doi:10.1038/srep44245 · Cited by 51
For the first fracture to be the last
Stolnicki, B., & Oliveira, L. G. (2016) · Revista Brasileira de Ortopedia (English Edition) · doi:10.1016/j.rboe.2016.01.005 · Cited by 51
Circadian disruption by shifting the light‐dark cycle negatively affects bone health in mice
Schilperoort, M., Bravenboer, N., Lim, J., Mletzko, K., Busse, B., van Ruijven, L. J., Kroon, J., Rensen, P. C. N., Kooijman, S., & Winter, E. M. (2019) · The FASEB Journal · doi:10.1096/fj.201901929r · Cited by 51
Review of osteoporosis pharmacotherapy for geriatric patients
Gates, B. J., Sonnett, T. E., DuVall, C. A. K., & Dobbins, E. K. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.12.004 · Cited by 51
Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial
Grey, A. B., Bolland, M. J., Wong, S., Horne, A. M., Gamble, G. D., & Reid, I. R. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2081 · Cited by 51
Decreased bone mineral density and periodontal management
Reddy, M. S., & Morgan, S. L. (2012) · Periodontology 2000 · doi:10.1111/j.1600-0757.2011.00400.x · Cited by 51
An open, prospective, non‐randomized, controlled, multicentre study to evaluate the clinical outcome of implant treatment in women over 60 years of age with osteoporosis/osteopenia: 1‐year results
Temmerman, A., Rasmusson, L., Kübler, A. C., Thor, A. L. I., & Quirynen, M. (2016) · Clinical Oral Implants Research · doi:10.1111/clr.12766 · Cited by 51
Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club
Gielen, E., Bergmann, P., Bruyère, O., Cavalier, E., Delanaye, P., Goemaere, S., Kaufman, J., Locquet, M., Reginster, J., Rozenberg, S., et al. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0266-3 · Cited by 54
Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
Mignot, M.-A., Taisne, N., Legroux, I., Cortet, B., & Paccou, J. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4215-9 · Cited by 53
Fracture liaison programs
Geusens, P., Bours, S., Wyers, C. E., & van den Bergh, J. P. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.03.016 · Cited by 50
Anti-resorptives in the management of osteoporosis
Miller, P. D. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.004 · Cited by 51
Mechanisms Underlying Normal Fracture Healing and Risk Factors for Delayed Healing
Cheng, C., & Shoback, D. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00501-5 · Cited by 50
Quality of Osteoporosis Care of Older Medicare Recipients with Fragility Fractures: 2006 to 2010
Liu, S. K., Munson, J. C., Bell, J., Zaha, R. L., Mecchella, J. N., Tosteson, A. N. A., & Morden, N. E. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12507 · Cited by 50
Impact of guideline implementation by a fracture nurse on subsequent fractures and mortality in patients presenting with non-vertebral fractures
Huntjens, K. M. B., van Geel, T. A. C. M., Geusens, P., Winkens, B., Willems, P. C. P. H., van den Bergh, J. P., Brink, P. R. G., & van Helden, S. H. (2011) · Injury · doi:10.1016/s0020-1383(11)70011-0 · Cited by 50
Screening for Atypical Femur Fractures Using Extended Femur Scans by DXA
van de Laarschot, D. M., Smits, A. A. A., Buitendijk, S. K. C., Stegenga, M. T., & Zillikens, M. C. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3164 · Cited by 50
Osteoporosis in men
Kaufman, J., & Goemaere, S. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.005 · Cited by 53
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M., & Haentjens, P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02010.x · Cited by 50
Self-citation
Intravenous bisphosphonates for postmenopausal osteoporosis: Safety profiles of zoledronic acid and ibandronate in clinical practice
Sieber, P., Lardelli, P., Kraenzlin, C. A., Kraenzlin, M. E., & Meier, C. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-012-0041-1 · Cited by 49
The Effect of Bisphosphonates on Fracture Healing Time and Changes in Bone Mass Density: A Meta-Analysis
Gao, Y., Liu, X., Gu, Y., Song, D., Ding, M., Liao, L., Wang, J., Ni, J., & He, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.688269 · Cited by 49
Clinical practice in nursing homes as a key for progress
Morley, J. E. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0039-4 · Cited by 49
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials
Barrett-Connor, E. L., Swern, A. S., Hustad, C. M., Bone, H., Liberman, U. A., Papapoulos, S. E., Wang, H., de Papp, A., & Santora, A. C. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1546-9 · Cited by 49
Ten-year risk of second hip fracture. A NOREPOS study
Omsland, T. K., Emaus, N., Tell, G. S., Ahmed, L. A., Nguyen, N. D., Gjesdal, C. G., Forsmo, S., Schei, B., Søgaard, A. J., & Meyer, H. E. (2012) · Bone · doi:10.1016/j.bone.2012.09.009 · Cited by 49
Osteoporosis: the emperor has no clothes
Järvinen, T. L. N., Michaëlsson, K., Aspenberg, P., & Sievänen, H. T. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12366 · Cited by 51

Authors: Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., & Boonen, S.
Affiliations: Veterans Health Administration (US)
University of Maryland, Baltimore (US)
McMaster University (CA)
Duke Medical Center (US)
Hvidovre Hospital (DK)
Oslo University Hospital (NO)
Savient Pharmaceuticals (United States) (US)
Novartis (Switzerland) (CH)
KU Leuven (BE)
ORCID: Magaziner, Jay S.
Adachi, Jonathan D.
Pieper, Carl F.
Nordsletten, Lars
Zhang, Jie
Mesenbrink, Peter
Eriksen, Erik Fink
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-11
Volume: 357
Issue: 18
Pages: 1799-1809
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa074941
PMC: PMC2324066
OpenAlex: W2163830908
Cited by: 2,003
References: 35
Citations by year: 2026: 53 · 2025: 88 · 2024: 67 · 2023: 75 · 2022: 78 · 2021: 119 · 2020: 104 · 2019: 94 · 2018: 92 · 2017: 79 · 2016: 97 · 2015: 92 · 2014: 106 · 2013: 115 · 2012: 122
FWCI: 160.83
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
PubMed Central (acceptedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: Amgen
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Sanofi
Savient Pharmaceuticals
Novo Nordisk
Servier
National Institute on Aging (K23AG024787)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Surgery › Hip and Femur Fractures
Keywords: zoledronic acid, hip fracture, bisphosphonates, fracture prevention, vertebral fractures, non-vertebral fractures, mortality, postoperative treatment, osteoporosis, adverse events, osteonecrosis of the jaw
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Calcium, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Vitamin D, Bone Density, Survival Analysis, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks